Context:

Recently scientists proved that the Nano-formulation of darkness hormone (melatonin) could be a therapeutic solution for Parkinson's disease.

About the research: 

• Researchers from the Institute of Nano Science and Technology (INST) in Mohali, India, explored the use of human serum albumin (HSA) nano-formulation for delivering melatonin to the brain (due to its biocompatibility).
• The team investigated the molecular mechanisms behind melatonin’s role in regulating oxidative stress.
• Their findings published in the journal ACS Applied Materials & Interfaces highlighted the significantly better in vitro and in vivo neuroprotective effect of nano-melatonin and the molecular/cellular dynamics it influences to regulate mitophagy.

Key findings:

• Nano-melatonin showed enhanced antioxidative and neuroprotective properties, improving mitophagy and mitochondrial biogenesis.
• Nano-melatonin's sustained release and targeted delivery to the brain resulted in higher therapeutic efficacy compared to regular melatonin.
• The study showed that nano-formulated melatonin provided a sustained release and improved bioavailability of the drug
• Increased antioxidative effects were linked to mitophagy induction through upregulation of BMI1, a key epigenetic regulator.
• The nano-formulation also protected neurons against toxicity induced by rotenone (a chemical linked to Parkinson’s).
• This method could lead to better treatments for Parkinson’s and possibly other conditions linked to cell damage.
• Continued research could establish melatonin as a safer drug, improving the quality of life for patients.